Not available for sale in Canada.
MIRVASO® (brimonidine) topical gel, 0.33%* is the first FDA-approved treatment developed and indicated for persistent (nontransient) facial redness of rosacea
Not available for sale in Canada.
MIRVASO® (brimonidine) topical gel, 0.33%* is the first FDA-approved treatment developed and indicated for persistent (nontransient) facial redness of rosacea